Andrx Announces Court of Appeals Decision in Antitrust Case.

Business Editors/High-Tech Writers

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--June 13, 2003

Andrx Corporation (Nasdaq:ADRX) today announced that the United States Court of Appeals for the Sixth Circuit has affirmed a June 2000 district court order which determined that the 1997 Stipulation and Agreement between Andrx and Hoechst Marion Roussel, Inc. (now Aventis Pharmaceuticals, Inc.) was a per se violation of the federal antitrust laws. The Stipulation was entered into in connection with then pending patent infringement litigation relating to Andrx's generic Cardizem(R) CD and was intended to ensure, among other things, that Andrx would be able to market this product. The district court must still determine the issues of whether the Stipulation caused any injury or damages. Andrx continues to believe that the Stipulation was pro-competitive, and enabled Andrx to market its product well before the district court that was handling the patent dispute was willing or able to do so, despite three and a half years of litigation. Andrx is considering its legal options, which include requesting legal review by either the full panel of the United States Court of Appeals for the Sixth Circuit or the United States Supreme Court.

In connection with the antitrust litigation, Andrx entered into a preliminary settlement with the direct purchaser class of plaintiffs in July 2002, which was granted final court approval in November 2002. Andrx also entered into a preliminary settlement with the indirect purchaser class of plaintiffs, as well as the attorney generals for all 50 states, the District of Columbia and Puerto Rico, in November 2002, which is pending final court approval. Today's court decision does not affect those settlements. In anticipation of those settlements and settlements with all other plaintiffs in the consolidated litigations (those plaintiffs who opted-out of the plaintiff classes or sued separately, which includes various Andrx customers and several related Blue Cross entities), in the second quarter of 2002, Andrx recorded an estimated litigation settlements charge of $60 million.

About Andrx Corporation:

Andrx Corporation develops and commercializes: bioequivalent versions of controlled-release brand name pharmaceuticals, using its proprietary drug delivery technologies; bioequivalent versions of specialty, niche and immediate-release pharmaceutical products, including oral contraceptives; and brand name or proprietary controlled-release formulations of existing immediate-release or controlled-release drugs where it believes the application of Andrx's drug delivery technologies may improve the efficacy or other characteristics of those products. Andrx also has distribution operations, which purchase primarily generic pharmaceuticals manufactured by third parties and sell them primarily to independent pharmacies, pharmacy chains which do not maintain their own central warehousing facilities, pharmacy buying groups and, to a lesser extent, physicians' offices.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the timing and outcome of litigation and government regulation. Andrx Corporation is also subject to other risks detailed herein or detailed from time to time in its filings with the U.S. Securities and Exchange Commission.

This release and additional information about Andrx Corporation is also available on the Internet at: http://www.andrx.com.